Lars Ove Tommy Westerlund

Dr. Lars Ove Tommy Westerlund


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
VMVeronica Milos
Veronica Milos
ÅBÅsa Bondesson
Åsa Bondesson
MMMartina Magnusson
Martina Magnusson
UJUlf Jakobsson
Ulf Jakobsson
LWLars Ove Tommy Westerlund
Lars Ove Tommy Westerlund
PMPatrik Midlöv
Patrik Midlöv
Falls are the most common cause of injuries and hospital admissions in the elderly. The Swedish National Board of Health and Welfare has created a list of drugs considered to increase the fall risk (FRIDs) and drugs that might cause/worsen orthostatism (ODs). This cross-sectional study was aimed to assess FRIDs and their correlation with falls in a sample of 369 community-dwelling and nursing home patients aged ≥75 years and who were using a multi-dose drug dispensing system.

31 March 2017 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
LWLars Ove Tommy Westerlund
Lars Ove Tommy Westerlund
SBSahra Barzi
Sahra Barzi
CBCecilia Bernsten
Cecilia Bernsten
Consumer views on safety of over-the-counter drugs, preferred retailers and information sources in Sweden: after re-regulation of the pharmacy market

28 November 2012 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LWLars Ove Tommy Westerlund
Lars Ove Tommy Westerlund
UGUlrika Gelin
Ulrika Gelin
EPElisabeth Pettersson
Elisabeth Pettersson
FSFredrik Skärlund
Fredrik Skärlund
KWKajsa Wågström
Kajsa Wågström
CRCarina Ringbom
Carina Ringbom

30 August 2023 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
KFKenji Fujita
Kenji Fujita
KHKjell H. Halvorsen
Kjell H. Halvorsen
NSNoriko Sato
Noriko Sato
JJJanja Jazbar
Janja Jazbar
PMPilar Modamio
Pilar Modamio
MTMartina Teichert
Martina Teichert
Background: Over the past 40 years, the tasks of pharmacists have shifted from logistic services to pharmaceutical care (PhC). Despite the increasing importance of measuring quality of care, there is no general definition of Quality Indicators (QIs) to measure PhC. Recognising this, a working group in a European association of PhC researchers, the Pharmaceutical Care Network Europe (PCNE), was established in 2020. Aim: This research aimed to review existing definitions of QIs and develop a definition of QIs for PhC. Method: A two-step procedure was applied. Firstly, a systematic literature review was conducted to identify existing QI definitions that were summarised. Secondly, an expert panel, comprised of 17 international experts from 14 countries, participated in two surveys and a discussion using a modified Delphi technique to develop the definition of QIs for PhC. Results: A total of 182 QI definitions were identified from 174 articles. Of these, 63 QI definitions (35%) cited one of five references as the source. Sixteen aspects that construct QI definitions were derived from the identified definitions. As a result of the Delphi study, the panel reached an agreement on a one-sentence definition of QIs for PhC: “quality indicators for pharmaceutical care are validated measurement tools to monitor structures, processes or outcomes in the context of care provided by pharmacists”. Conclusion: Building upon existing definition of QIs, an international expert panel developed the PCNE definition of QIs for PhC. This definition is intended for universal use amongst researchers and healthcare providers in PhC.

16 December 2014 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
VMVeronica Milos
Veronica Milos
LWLars Ove Tommy Westerlund
Lars Ove Tommy Westerlund
PMPatrik Midlöv
Patrik Midlöv
ESEva Lena Strandberg
Eva Lena Strandberg
Drug therapy in primary care is a challenge for general practitioners (GPs) and the prescribing decision is influenced by several factors. GPs obtain drug information in different ways, from evidence-based sources, their own or others’ experiences, or interactions with opinion makers, patients or colleagues. The need for objective drug information sources instead of drug industry-provided information has led to the establishment of local drug and therapeutic committees. They annually produce and implement local treatment guidelines in order to promote rational drug use. This study describes Swedish GPs’ attitudes towards locally developed evidence-based treatment guidelines. Three focus group interviews were performed with a total of 17 GPs working at both public and private primary health care centres in Skåne in southern Sweden. Transcripts were analysed by conventional content analysis. Codes, categories and themes were derived from data during the analysis. We found two main themes: GP-related influencing factors and External influencing factors. The first theme emerged when we put together four main categories: Expectations and perceptions about existing local guidelines, Knowledge about evidence-based prescribing, Trust in development of guidelines, and Beliefs about adherence to guidelines. The second theme included the categories Patient-related aspects, Drug industry-related aspects, and Health economic aspects. The time-saving aspect, trust in evidence-based market-neutral guidelines and patient safety were described as key motivating factors for adherence. Patient safety was reported to be more important than adherence to guidelines or maintaining a good patient-doctor relationship. Cost containment was perceived both as a motivating factor and a barrier for adherence to guidelines. GPs expressed concerns about difficulties with adherence to guidelines when managing patients with drugs from other prescribers. GPs experienced a lack of time to self-inform and difficulties managing direct-to-consumer drug industry information. Patient safety, trust in development of evidence-based recommendations, the patient-doctor encounter and cost containment were found to be key factors in GPs’ prescribing. Future studies should explore the need for transparency in forming and implementing guidelines, which might potentially increase adherence to evidence-based treatment guidelines in primary care.

18 September 2018
Verified
Book Chapter
Closed access
PDF file
LWLars Ove Tommy Westerlund
Lars Ove Tommy Westerlund